Carvedilol Tablet, Film Coated
Product Images NDC 71335-0273

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 71335-0273). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A survival analysis chart titled 'Survival Analysis for COPERNICUS (Intent-to-Treat)' showing percentage mortality over months. The graph compares two groups: Placebo and Carvedilol, with the placebo group exhibiting higher mortality percentages over time. A p-value of 0.004 is indicated on the chart, demonstrating statistical significance.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A forest plot illustrating effects on mortality for subgroups in the COPERNICUS study. The chart presents hazard ratios on the horizontal axis with subgroup categories including gender, age, race, diabetic status, ischemic status, heart rate, systolic blood pressure, spironolactone use, and all patients. Each subgroup is represented by a point estimate and confidence interval along the hazard ratio scale.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A survival analysis line graph titled 'Survival Analysis for CAPRICORN (Intent-to-Treat)' showing percent mortality over 24 months. The graph compares two groups labeled 'Placebo' and 'Carvedilol,' with mortality increasing over time for both groups. The Carvedilol group shows a lower percent mortality compared to the Placebo group throughout the timeline. The x-axis represents months and the y-axis represents percent mortality, with a noted P-value of 0.03.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A figure titled 'Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratio plots for various patient subgroups. The chart displays hazard ratios with confidence intervals for groups based on age, sex, timing post-myocardial infarction, prior IV/oral beta-blocker use, Killip class, thrombolytic therapy, PTCA, heart failure history, diuretic use, angina status, hypertension, diabetes, heart rate, and systolic blood pressure.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure of Carvedilol is depicted, showing its specific arrangement of atoms and bonds typical for this active pharmaceutical ingredient used in its 25 mg strength formulation.*

FDA Label Image

Label (Lbl713350273)

Carvedilol 25 mg tablet label by Bryant Ranch Prepack. The label indicates the product is a white oval tablet with the imprint 'E;04' and compares to Coreg 25 mg tablet from Aurobindo Pharma USA Inc. It includes storage instructions to keep at room temperature between 20°-25°C (68°-77°F) and a warning to keep all drugs out of reach of children. The package size is 100 tablets. The NDC displayed is 71335-0273-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.